The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company’s drugs for benign prostatic hypertrophy market report forecasts the drugs for benign prostatic hypertrophy market size to grow to $8.18 Billion by 2027, with a CAGR (compound annual growth rate) of more than 4%.

Learn More On The Drugs For Benign Prostatic Hypertrophy Market Report 2023 – https://www.thebusinessresearchcompany.com/report/drugs-for-benign-prostatic-hypertrophy-global-market-report

Drugs For Benign Prostatic Hypertrophy Market Size Forecast
The global drugs for benign prostatic hypertrophy market is expected to grow from $6.45 billion in 2022 to $6.86 billion in 2023 at a compound annual growth rate (CAGR) of 6.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global drugs for benign prostatic hypertrophy market size is expected to grow to $8.18 billion in 2027 at a CAGR of 4.5%.

North America held the largest drugs for benign prostatic hypertrophy market share, and Middle East was the fastest-growing region in 2022.

Key Drugs For Benign Prostatic Hypertrophy Market Driver ­– Rise In The Male Geriatric Population Globally
According to the United Nations’ 2019 World Population Ageing Report, the number of people aged 65 years or above was 703 million in 2019 and is expected to double to around 1.5 billion by 2050. According to the National Institute of Health (NIH), Benign Prostatic Hyperplasia affects around 50% of men aged between 51 and 60 years and up to 90% of men aged over 80 years.

Request for A Sample Of The Global Drugs For Benign Prostatic Hypertrophy Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2594&type=smp

Key Drugs For Benign Prostatic Hypertrophy Market Trend – Adopting Combination Drugs
Combination drugs are increasingly being used in the treatment of Benign Prostatic Hypertrophy as they are more effective and help prevent disease progression. A combination drug includes two or more active pharmaceutical ingredients (APIs) combined in a single dosage form. These drugs reduce the development of drug resistance, have fewer side effects, and low treatment failure rate. For instance, Duodart, a combination of dutasteride and tamsulosin hydrochloride is increasingly being prescribed for the treatment of Benign Prostatic Hypertrophy.

Drugs For Benign Prostatic Hypertrophy Market Segment
1) By Type: Alpha Blocker, 5-alpha Reductase Inhibitor, Phosphodiesterase-5 Inhibitor, Other Types
2) By End User: Hospital Pharmacies, Retail Pharmacies, Other End-Users
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Drugs For Benign Prostatic Hypertrophy Market Major Players and Strategies
Major players in the drugs for benign prostatic hypertrophy market are Allergan PLC., Astellas Pharma Inc., Boehringer Ingelheim, Eli Lilly and Company, GlaxoSmithKline PLC., Teva Pharmaceutical Industries Limited, Sanofi, Nymox Pharmaceutical Corporation, and AEternaZentaris Inc.

The Drugs For Benign Prostatic Hypertrophy Global Market Report 2023 covers regional data on drugs for benign prostatic hypertrophy market size, drugs for benign prostatic hypertrophy market trends and drivers, opportunities, strategies, and drugs for benign prostatic hypertrophy market competitor analysis. The countries covered in the drugs for benign prostatic hypertrophy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

The drug benign prostatic hypertrophy refers to benign prostatic hypertrophy drugs that are used to treat enlarged prostate glands by relaxing bladder neck muscles and muscle fibres in the prostate, making urination easier. Benign Prostatic Hypertrophy is commonly seen in men older than 50.

View More Reports Related To The Drugs For Benign Prostatic Hypertrophy Market –
Drugs For Erectile Dysfunction Global Market Report 2023
Drugs For Immunotherapy Global Market Report 2023
Drugs For Hormonal Replacement Therapy Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: